CGC Strangle Strategy
CGC (Canopy Growth Corporation), in the Healthcare sector, (Drug Manufacturers - Specialty & Generic industry), listed on NASDAQ.
Canopy Growth Corporation (CGC), alongside its affiliated businesses, specializes in the cultivation, marketing, and retail of both cannabis and hemp-derived products. These offerings are designed for both recreational consumption and therapeutic uses, with its primary commercial reach extending across Canada, the United States, and Germany. The company structures its operations into two main divisions: Global Cannabis and a diverse portfolio of Other Consumer Products. Its extensive product range features dried cannabis flower, various extracts and concentrates, infused beverages, edible gummies, and vape cartridges. Canopy Growth distributes these items under numerous well-known brands, such as Tweed, 7ACRES, Martha Stewart CBD, and Spectrum Therapeutics, among others. Originally founded as Tweed Marijuana Inc., the enterprise adopted its current name, Canopy Growth Corporation, in September 2015.
CGC (Canopy Growth Corporation) trades in the Healthcare sector, specifically Drug Manufacturers - Specialty & Generic, with a market capitalization of approximately $399.3M, a beta of 2.41 versus the broader market, a 52-week range of 0.844-2.38, average daily share volume of 9.6M, a public-listing history dating back to 2014, approximately 1K full-time employees. These structural characteristics shape how CGC stock options price implied volatility around earnings windows, capital events, and macro-driven sector rotations.
A beta of 2.41 indicates CGC has historically moved more than the broader market, amplifying both the directional payoff and the realized volatility relative to an index-equivalent position.
What is a strangle on CGC?
A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money.
Current CGC snapshot
As of June 30, 2026, spot at $0.98, ATM IV 89.16%, IV rank 33.90%, expected move 25.56%. The strangle on CGC below is built from the same end-of-day chain, with strikes snapped to listed contracts and premiums pulled from the bid/ask midpoint at a 31-day expiry.
Why this strangle structure on CGC specifically: CGC IV at 89.16% is mid-range versus its 1-year history, so strategy selection should anchor more to the directional thesis than to the IV regime, with a market-implied 1-standard-deviation move of approximately 25.56% (roughly $0.25 on the underlying). The 31-day window matched to the front-month expiry keeps theta exposure bounded while still capturing the post-snapshot move; longer-dated CGC expiries trade a higher absolute premium for lower per-day decay. Position sizing on CGC should anchor to the underlying notional of $0.98 per share and to the trader's directional view on CGC stock.
CGC strangle setup
The CGC strangle below is built from the end-of-day chain, with each option leg priced at the bid/ask midpoint of its listed strike. With CGC near $0.98, the first option leg uses a $1.03 strike; additional legs (when the strategy has them) anchor to spot-relative offsets. Premiums come from the bid/ask midpoint on the listed CGC chain at a 31-day expiry; the cross-strike IV skew is reflected directly in the per-leg values rather than approximated. Quantity sizing assumes one contract per option leg (or 100 CGC shares for the stock leg in covered calls and collars).
| Action | Type | Strike / Basis | Premium (est) |
|---|---|---|---|
| Buy 1 | Call | $1.03 | N/A |
| Buy 1 | Put | $0.93 | N/A |
CGC strangle risk and reward
- Net Premium / Debit
- N/A
- Max Profit (per contract)
- Unbounded
- Max Loss (per contract)
- Unbounded
- Breakeven(s)
- None on modeled curve
- Risk / Reward Ratio
- N/A
Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit.
CGC strangle payoff curve
Modeled P&L at expiration across a range of underlying prices for the strangle on CGC. Each row is one sampled price point from the computed payoff curve; the full curve uses 200 price points internally before being summarized into 10 rows here.
When traders use strangle on CGC
Strangles on CGC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CGC chain.
CGC thesis for this strangle
The market-implied 1-standard-deviation range for CGC extends from approximately $0.73 on the downside to $1.23 on the upside. A CGC long strangle is the OTM cousin of the straddle: lower up-front cost but the underlying has to travel further past either OTM strike before the position turns profitable at expiration. Current CGC IV rank near 33.90% is mid-range against its 1-year distribution, so the IV signal is neutral; the strangle thesis on CGC should anchor more to the directional view and the expected-move geometry. As a Healthcare name, CGC options can move on sector-level news flow (peer earnings, regulatory updates, industry-specific macro data) in addition to CGC-specific events.
CGC strangle positions are structurally neutral / high-volatility (long premium, OTM); the modeled P&L assumes European-style exercise at expiration and ignores early assignment, transaction costs, dividends paid before expiry on the stock leg (when present), and the bid-ask spread on the listed chain. CGC positions also carry Healthcare sector concentration risk; news flow inside the sector (peer earnings, regulatory shifts, supply-chain headlines) can move CGC alongside the broader basket even when CGC-specific fundamentals are unchanged. Always rebuild the position from current CGC chain quotes before placing a trade.
Frequently asked questions
- What is a strangle on CGC?
- A strangle on CGC is the strangle strategy applied to CGC (stock). The strategy is structurally neutral / high-volatility (long premium, OTM): A long strangle buys an OTM call and an OTM put at offset strikes, cheaper than a straddle but requiring a larger underlying move to profit since both wings start out-of-the-money. With CGC stock trading near $0.98, the strikes shown on this page are snapped to the nearest listed CGC chain strike and the premiums come straight from the end-of-day bid/ask midpoint.
- How are CGC strangle max profit and max loss calculated?
- Upside max profit is unbounded; downside max profit is bounded at the put strike minus the combined debit (reached at zero). Max loss equals the combined debit times 100 (reached anywhere between the two OTM strikes). Two breakevens at call-strike plus debit and put-strike minus debit. For the CGC strangle priced from the end-of-day chain at a 30-day expiry (ATM IV 89.16%), the computed maximum profit is unbounded per contract and the computed maximum loss is unbounded per contract. Live intraday quotes will differ as the chain moves through the trading session.
- What is the breakeven for a CGC strangle?
- The breakeven for the CGC strangle priced on this page is no defined breakeven on the modeled curve at expiration, derived from end-of-day chain premiums. Breakeven is the underlying price at which the strategy's P&L crosses zero ignoring transaction costs and assignment risk. The current CGC market-implied 1-standard-deviation expected move is approximately 25.56%; if the move sits well outside the breakeven distance, the structure's risk-reward becomes correspondingly tighter.
- When should you consider a strangle on CGC?
- Strangles on CGC are the cheaper cousin of the straddle - traders use them when they want a large directional move but are willing to give up the inner-strike sensitivity in exchange for a lower up-front debit on the CGC chain.
- How does current CGC implied volatility affect this strangle?
- CGC ATM IV is at 89.16% with IV rank near 33.90%, which is mid-range against its 1-year history. Strategy selection depends more on directional thesis and expected move than on a strong IV signal.